in aggiunta ad altri medicinali per il trattamento del diabete. Sia EMA che AIFA hanno autorizzato invece Wegovy in associazione a dieta ed esercizio fisico per la perdita di peso , ma solo in casi specifici: un BMI (indice di massa corporea) pari o superiore a 30 kg/m (obesit) oppure un BMI pari o superiore a 27 kg/m ma inferiore a 30 kg/m (sovrappeso) e che presentano problemi di salute correlati al peso (come diabete, ipertensione, livelli anomali di grassi nel sangue, "apnea notturna ostruttiva" o una storia di infarto, ictus o problemi ai vasi sanguigni). In tutti i casi, necessaria la ricetta: un medico che deve prescrivere e monitorare la terapia
Diagnost (Basel)
Exendin-4 also reduced vascular immunoglobulin G extravasation, indicating reduced endothelial leakage in the late inflammatory response to ischemia [71]
Age is another major risk factor: HF has been reported to affect around 1%2% of all adults ( The pathophysiology of HF has been extensively reviewed by others ( As mentioned earlier, HF is traditionally considered as three main phenotypes: HFrEF, HFmrEF and HFpEF ( Currently available pharmacotherapeutics options in HF mostly remain focused on HFrEF, where treatments strategies aim at relief of symptoms, improving quality of life, and prolonging the life of the affected individual ( GLP-1 receptor agonism in heart failure Clinical evidence Only a few clinical investigations studying the effects of GLP-1 RAs specifically in HF (all in HFrEF) have been reported as briefly discussed below
WONDERS OF L-CARNITINE: L-Carnitine is an amino acid-rich supplement that helps you lose weight and reduce fatigue